14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DORM vs IPAR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IPAR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)
IPAR Overall Winner
6-Pillar Tally: DORM 3 – 3 IPAR
Matrix Metrics: DORM 5 – 5 IPAR
As of Nov 16, 2026, Interparfums, Inc. (IPAR) is the stronger overall head-to-head candidate over Dorman Products, Inc. New (DORM) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). DORM carries a Unified Composite Score of 36.0/100 (SELL) at $131.38 (14.5x Forward P/E, 15.6% operating margin), whereas IPAR carries 31.7/100 (SELL) at $133.94 (26.2x Forward P/E, 17.9% operating margin).
Composite vs. Pillar Nuance: While DORM currently prints a higher short-term Unified Composite Score (36.0/100 SELL vs. IPAR 31.7/100 SELL), IPAR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.9% vs. 15.6% operating margin) and revenue trajectory (+0.0% vs. +3.3% YoY).
Defensive Composite Rating Caution: Although IPAR compares more favorably head-to-head, both DORM (36.0/100 SELL) and IPAR (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DORM vs IPAR. Trailing 12-month operating profitability (DORM 15.6% vs IPAR 17.9%) and valuation multiples (DORM 14.5x vs IPAR 26.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Auto Parts value chain with $3.9B market capitalization and 15.6% operating margin.
OpEx & R&D Reinvestment25.5% of Rev ($554M)
90D Engineering Disclosures0 Published
IPAR Moat ProfileScale & Operating Efficiency Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $4.2B market capitalization and 17.9% operating margin.
OpEx & R&D Reinvestment41.9% of Rev ($629M)
90D Engineering Disclosures0 Published
Investor FAQ DORM vs IPAR Key Questions & Quantitative Answers
As of Nov 16, 2026, Interparfums, Inc. (IPAR) is the stronger overall head-to-head candidate over Dorman Products, Inc. New (DORM) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). DORM carries a Unified Composite Score of 36.0/100 (SELL) at $131.38 (14.5x Forward P/E, 15.6% operating margin), whereas IPAR carries 31.7/100 (SELL) at $133.94 (26.2x Forward P/E, 17.9% operating margin). Composite vs. Pillar Nuance: While DORM currently prints a higher short-term Unified Composite Score (36.0/100 SELL vs. IPAR 31.7/100 SELL), IPAR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.9% vs. 15.6% operating margin) and revenue trajectory (+0.0% vs. +3.3% YoY). Defensive Composite Rating Caution: Although IPAR compares more favorably head-to-head, both DORM (36.0/100 SELL) and IPAR (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DORM leads the Growth & Scale pillar: DORM posts +3.3% YoY revenue growth and -20.2% YoY earnings growth on $2.17B TTM revenue (41.1% gross margin, 15.6% operating margin), compared with IPAR at +0.0% YoY revenue growth and +3.9% YoY earnings growth on $1.50B TTM revenue (59.8% gross margin, 17.9% operating margin). On trailing 12-month operating scale, DORM generates $2.17B in USD-normalized revenue versus $1.50B for IPAR. In operating R&D and SG&A reinvestment, DORM deploys 25.5% of Rev ($554M) (0 90-day corporate R&D disclosures) versus 41.9% of Rev ($629M) (0 disclosures) for IPAR.
DORM screens cheaper on headline valuation multiples. DORM trades at 14.5x Forward P/E, 19.7x Trailing P/E, 1.17x PEG, and 2.0x EV/Revenue (12.4% FCF margin), whereas IPAR trades at 26.2x Forward P/E, 24.6x Trailing P/E, 3.20x PEG, and 2.8x EV/Revenue (19.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DORM (13.3% ROE) versus IPAR (19.0% ROE) capital efficiency.
In options market volatility and institutional positioning, DORM carries 37.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.70β · 34% Vol realized risk). By comparison, IPAR carries 41.0% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 43% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.